DCN has also been shown to be released by ferroptotic cancer cells in PDAC development and, when released, acts as a damage‐associated molecular pattern (DAMP) recognised by macrophages via advanced glycosylation end‐product specific receptor (AGER), triggering an inflammatory response [7]. This evidence concerns the gene DCN and cancer.